γ-aminobutyric acid receptor B signaling drives glioblastoma in females in an immune-dependent manner

Author:

Bayik Defne1,Pathak Asmita1ORCID,Sra Palavalasa2,Knott Maxon3,Colon Bruno3,Ciervo Erika4,Zhou Yadi5,Mitchell Jonathan3,Pumar Oriana3,Wong Harrison6,Zhang Li2,Susic Nikola3,Shah Khushi3,Kay Kristen7,Chin Diana7,Johnson Sadie5,Cheng Feixiong5ORCID,Lyssiotis Costas2ORCID,Watson Dionysios8,Ceccarelli Michele1,Shah Ashish1,Wahl Daniel2ORCID,Lathia Justin9ORCID

Affiliation:

1. University of Miami

2. University of Michigan

3. Leonard M. Miller School of Medicine, University of Miami

4. Università degli Studi di Napoli Federico II, Napoli

5. Cleveland Clinic

6. University of Michigan, Ann Arbor

7. Lerner Research Institute, Cleveland Clinic

8. Sylvester Comprehensive Cancer Center, University of Miami

9. Cleveland Clinic Foundation

Abstract

Abstract

Sex differences in immune responses impact cancer outcomes and treatment response, including in glioblastoma (GBM). However, host factors underlying sex specific immune-cancer interactions are poorly understood. Here, we identify the neurotransmitter γ-aminobutyric acid (GABA) as a driver of GBM-promoting immune response in females. We demonstrated that GABA receptor B (GABBR) signaling enhances L-Arginine metabolism and nitric oxide synthase 2 (NOS2) expression in female granulocytic myeloid-derived suppressor cells (gMDSCs). GABBR agonist and GABA analog promoted GBM growth in females in an immune-dependent manner, while GABBR inhibition reduces gMDSC NOS2 production and extends survival only in females. Furthermore, female GBM patients have enriched GABA transcriptional signatures compared to males, and the use of GABA analogs in GBM patients is associated with worse short-term outcomes only in females. Collectively, these results highlight that GABA modulates anti-tumor immune response in a sex-specific manner, supporting future assessment of GABA pathway inhibitors as part of immunotherapy approaches.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3